NNN Nanosynth Group Plc

TIDMRMS

RNS Number : 7935V

Remote Monitored Systems PLC

19 April 2021

19 April 2021

Remote Monitored Systems plc

("RMS" or the "Company")

Board appointments

Further to the announcement of 18 February 2021, the Company is pleased to announce the appointments of Dr Gareth Cave and Dr Felicity Sartain as non-executive directors of the Company, effective immediately. Dr Felicity Sartain will be an independent non-executive director.

Dr Gareth Cave is a founder and Chairman of Pharm2Farm Ltd ("P2F"), the Company's wholly owned subsidiary. Dr Cave gained his BSc, MSc and PhD in Chemistry from the University of Warwick. He subsequently co-established the Australian Centre for Green Chemistry at Monash University in Australia, whilst also pioneering a new "green" solvent-free chemical reaction process, that later led to the two patents licenced to P2F to manufacture and fictionalise their nanotechnology processes. Dr Cave later went on to work as an academic at the Universities of Leeds, Liverpool and University of Missouri, USA before returning to the UK at Nottingham Trent University in 2005 where he is currently Head of Inorganic Chemistry. His current interdisciplinary university research group, of 11 PhD's utilise nanotechnology across a plethora of applications from cancer immunology, and treatments of Alzheimer's through to food security - both plant and livestock.

Dr Felicity Sartain has a multi-disciplinary background established over 10 years including managerial, commercial and research in the Healthcare, Life Science and Nanotechnology sectors. She holds a PhD in Biotechnology from the University of Cambridge and an MSc in Chemistry at the University of York. She has also undertaken Post-Doctoral Research at the University of Cambridge following an industrial placement with GlaxoSmithKline. Felicity is currently Chief Operating Officer of Closed Loop Medicine where she initially worked as a consultant from September 2017.

Antony Legge, Executive Chairman of RMS, said:

" We are delighted to welcome both Gareth and Felicity to the Board. They are both highly accomplished in their fields with deep knowledge and experience in nanotechnology. The appointments strengthen and extend the Board's skill set, and we very much look forward to benefitting over the coming years as their contributions support RMS's growth trajectory."

The following disclosures are required regarding Drs Cave and Sartain's appointment to the RMS Board pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies ("AIM Rules"):

Full name: Dr Gareth Wynn Vaughan Cave

Age: 46

Current directorships/partnerships: Pharm2Farm Ltd

Former directorships/partnerships in the last 5 years: N/A

Dr. Cave currently holds 289,645,185 ordinary shares in the Company, representing 13.9% of the Company's total issued share capital.

Full name: Dr Felicity Kate Sartain

Age: 41

Current directorships/partnerships: Profiscio Ltd

   Previous directorships/partnerships in the last five years:   NanoScientium Ltd 

Save as set out above, there is no further information to be disclosed in respect of Dr Gareth Cave and Dr Felicity Sartain under Schedule 2(g) of the AIM Rules.

- ENDS -

ENQUIRIES :

 
 Remote Monitored Systems plc          via IFC Advisory 
 Antony Legge (Executive Chairman) 
 
 SP Angel Corporate Finance LLP        +44 20 3470 0470 
 Nominated Adviser and Joint Broker 
 Stuart Gledhill 
 Caroline Rowe 
 
 Peterhouse Capital Limited            +44 20 7469 0930 
 Joint Broker 
 Lucy Williams 
 
 IFC Advisory Ltd                      +44 20 3934 6630 
 Graham Herring 
 Zach Cohen 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOAGPUCACUPGGAQ

(END) Dow Jones Newswires

April 19, 2021 02:00 ET (06:00 GMT)

Nanosynth (LSE:NNN)
Historical Stock Chart
From Mar 2024 to Apr 2024

Nanosynth (LSE:NNN)
Historical Stock Chart
From Apr 2023 to Apr 2024